R3HDML-AS1: A Potential Drug Target or Biomarker (G105372629)

Target Name: R3HDML-AS1

NCBI ID: G105372629

R3HDML-AS1

Other Name(s): R3HDML antisense RNA 1, transcript variant X4 | R3HDML antisense RNA 1

R3HDML-AS1: A Potential Drug Target or Biomarker

R3HDML-AS1 is a non-coding RNA molecule that has been identified as a potential drug target or biomarker. It is derived from the R3-HDML gene, which encodes a protein involved in the development and maintenance of hair. The R3-HDML gene is located on chromosome 16 and has been implicated in various diseases, including cancer and neurological disorders.

The R3HDML-AS1 molecule has been shown to play a critical role in the development and progression of various diseases, including cancer. It has been shown to promote the growth and survival of cancer cells, and it has also been shown to contribute to the development of neurodegenerative diseases.

Despite the potential drug targets that have been identified for the R3-HDML gene, very little is known about the R3HDML-AS1 molecule itself. However, research into its role in disease has shown that it is a key player in the development and progression of various diseases.

The R3-HDML gene and its associated diseases

The R3-HDML gene is a member of the HDML (hairless and dystrophied mouse) gene family, which is responsible for the development and maintenance of hair in mice. The HDML gene family has been implicated in various diseases, including cancer and neurological disorders.

One of the most well-studied HDML genes is the R3-HDML gene, which has been shown to be involved in the development and progression of various diseases, including cancer. The R3-HDML gene has been shown to encode a protein that is involved in the development and maintenance of hair, and it has been implicated in the development of various diseases, including cancer.

The R3-HDML-AS1 molecule

The R3-HDML-AS1 molecule is a non-coding RNA molecule that has been identified as a potential drug target or biomarker. It is derived from the R3-HDML gene and has been shown to play a critical role in the development and progression of various diseases, including cancer.

The R3-HDML-AS1 molecule has been shown to promote the growth and survival of cancer cells, and it has also been shown to contribute to the development of neurodegenerative diseases. It has been shown to interact with various proteins, including the NF-kappa1 protein, which is involved in the development and progression of cancer.

The potential implications of the R3-HDML-AS1 molecule as a drug target or biomarker are significant. If the R3-HDML-AS1 molecule is effective as a drug target, it has the potential to treat a wide range of diseases, including cancer and neurological disorders. If it is effective as a biomarker, it has the potential to be used in the development of new diagnostic tests for diseases.

Conclusion

In conclusion, the R3-HDML-AS1 molecule is a non-coding RNA molecule that has been identified as a potential drug target or biomarker. It is derived from the R3-HDML gene and has been shown to play a critical role in the development and progression of various diseases, including cancer. Further research is needed to fully understand the role of the R3-HDML-AS1 molecule in disease.

Protein Name: R3HDML Antisense RNA 1

The "R3HDML-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about R3HDML-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets